Drug Trial Radar · NCT04419506
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 19, 2026Latest source record: Nov 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Jul 28, 2020
Primary completion
Oct 6, 2021
Study completion Oct 15, 2021
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study. The purpose of the study is to find out whether a medicine called BI 1015550 can slow down the worsening of lung function. Participants are in the study for about 4 months. During this time, they visit the study site about 7 times. At the beginning, they visit the study site every 2 weeks. After 1 month of treatment, they visit the study site every 4 weeks. The participants are put into 2 groups by chance. 1 group gets BI 1015550. The other group gets placebo. Placebo tablets look like BI 1015550 tablets but contain no medicine. The participants take BI 1015550 or placebo tablets twice a day. The participants have lung function tests at study visits. The results of the lung function tests are compared between the BI 1015550 group and the placebo group. The doctors also regularly check the general health of the participants.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
BI 1015550Drug
18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
PlaceboDrug
placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Change From Baseline in Forced Vital Capacity (FVC) at 12 WeeksTime frame: Baseline (day 1) and week 12.
Locations
75 sites in 22 countries. Site status is shown where the registry gives one.
St. Francis Medical Institute
Clearwater, Florida
University of Florida
Gainesville, Florida
University of Kansas Medical Center
Kansas City, Kansas
Mayo Clinic, Rochester
Rochester, Minnesota
The Lung Research Center, LLC
Chesterfield, Missouri
Creighton University
Omaha, Nebraska
Southeastern Research Center
Winston-Salem, North Carolina
The Ohio State University Wexner Medical Center
Columbus, Ohio
Temple University Hospital
Philadelphia, Pennsylvania
Diagnostics Research Group
San Antonio, Texas
University of Utah Health Sciences Center
Salt Lake City, Utah
Centro de Investigaciones Metabólicas (CINME)
C.a.b.a, Argentina
The Alfred Hospital
Melbourne, Victoria, Australia
LKH-Univ. Hospital Graz
Graz, Austria
St. Paul's Hospital
Vancouver, British Columbia, Canada
Dr. Georges-L.-Dumont University Hospital Centre
Moncton, New Brunswick, Canada
Queen's University
Kingston, Ontario, Canada
Dr. Syed Anees Medicine Professional Corporation
Windsor, Ontario, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
Instituto Nacional del Tórax
Providencia, Santiago de Chile, Chile
Centro de Investigación del Maule
Talca, Chile
Peking Union Medical College Hospital
Beijing, China
The Second Hospital of Jilin University
Changchun, China
West China Hospital
Chengdu, China
Zhongshan Hospital Fudan University
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China
University Hospital Na Bulovce, Prague
Prague, Czechia
University Thomayer's Hospital
Praha 4 - Krc, Czechia
Aarhus University Hospital
Aarhus N, Denmark
Herlev and Gentofte Hospital
Hellerup, Denmark
Odense University Hospital
Odense C, Denmark
HYKS Keuhkosairauksien tutkimusyksikkö
Helsinki, Finland
KYS, Keuhkosairauksien
Kuopio, Finland
Oulun yliopistollinen keskussairaala
Oulu, Finland
Tampere University Hospital
Tampere, Finland
TYKS
Turku, Finland
Fachkrankenhaus Coswig GmbH
Coswig, Germany
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
Essen, Germany
Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
Heidelberg, Germany
Lungenfachklinik Immenhausen
Immenhausen, Germany
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.